No correlation between COMT genotype and entacapone benefits in Parkinson's disease
- Authors
- Kim J.S.[Kim J.S.]; Kim J.-Y.[Kim J.-Y.]; Kim J.-M.[Kim J.-M.]; Kim J.W.[Kim J.W.]; Chung S.J.[Chung S.J.]; Kim S.R.[Kim S.R.]; Kim M.J.[Kim M.J.]; Kim H.-T.[Kim H.-T.]; Choi K.-G.[Choi K.-G.]; Shin D.-I.[Shin D.-I.]; Sung Y.H.[Sung Y.H.]; Lee K.-S.[Lee K.-S.]; Kim H.-J.[Kim H.-J.]; Cho J.[Cho J.]; Park M.Y.[Park M.Y.]; Park H.-Y.[Park H.-Y.]; Choi S.-M.[Choi S.-M.]; Park K.-W.[Park K.-W.]; Lee H.-W.[Lee H.-W.]; Ahn T.-B.[Ahn T.-B.]; Kwon O.D.[Kwon O.D.]; Kim S.-J.[Kim S.-J.]; Jeon B.S.[Jeon B.S.]
- Issue Date
- 2011
- Citation
- Neurology Asia, v.16, no.3, pp.211 - 216
- Indexed
- SCIE
SCOPUS
- Journal Title
- Neurology Asia
- Volume
- 16
- Number
- 3
- Start Page
- 211
- End Page
- 216
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/71909
- ISSN
- 1823-6138
- Abstract
- Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily ""off"" duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily ""on"" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased ""on"" duration and improved motor function in all COMT genotypes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/71909)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.